Uvod: U razvoj OSA-e uključeni su, osim anatomskih varijabli i statičko-dinamički
patofiziološki čimbenici zbog kojih dolazi do repetitivne opstrukcije disanja tijekom noći koja …

Obstructive sleep apnea (OSA) has become major public concern and is continuously
investigated in new aspects of pathophysiology and management. Urotensin II (UII) is a …

Abstract Objective Human urotensin II (UII) acts on the urotensin (UT) receptor and is the
most potent mammalian vasoconstrictor identified to date. The role of UII in human …

Urotensin II (UTII) is recently discovered neurohumoral factor influencing function and
structure of the myocardium and remodeling of the vessels, and it may contribute to …

Urotensin II (UII) is a potent vasoactive cyclic peptide thought to play a role in myocardial
hypertrophy and remodelling. We therefore determined UII plasma levels in congestive heart …

BACKGROUND: The hyperdynamic circulation of hepatic cirrhosis is related to decreased
systemic vascular resistance due to arterial vasodilation. Urotensin II plasma levels are …

Objective. Urotensin II is a potent vasoactive peptide that has been implicated in the
pathophysiology of many diseases. There is no study reporting the role and level of this …

Urotensin II (UTN) is a cyclic eleven amino acid peptide that can induce endothelial
independent vasoconstriction and endothelial dependent vasodilatation in human …

IMPLICATIONS: Urotensin II is the most potent known endogenous human vasoconstrictor.
In this pilot study, we report for the first time that cerebrospinal fluid levels are smaller than …

BACKGROUND: Hypertension is diagnosed in approximately 50% of patients with acute
myocardial infarction. Urotensin II (U-II)—a potent vasoactive peptide shown to be elevated …